TAFAZZIN and cardiomyopathy: TAZ deficiency in humans results in cardiomyopathy, neutropenia, myopathy, growth retardation, and 3-methylglutaconic aciduria through a deficiency of the phospholipid cardiolipin (1,3-bis(sn-3′-phosphatidyl)-sn-glycerol) in the inner mitochondrial membrane (Zegallai & Hatch, 2021).